Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377692 | 0.84 | PKM (0.41) | — | |
| SCHEMBL377424 | 0.84 | PKM (0.41) | — | |
| SCHEMBL2765765 | 0.84 | MGLL (0.49) | MGLLFAAHPTGDR2 | |
| SCHEMBL377606 | 0.79 | HIF1A (0.34) | FAAH | |
| SCHEMBL377619 | 0.76 | MGLL (0.43) | MGLLFAAHPTGDR2 | |
| SCHEMBL2766913 | 0.73 | MGLL (0.48) | MGLLFAAHPTGDR2 | |
| SCHEMBL2765722 | 0.72 | PTGDR2 (0.48) | MGLLFAAHPTGDR2 | |
| SCHEMBL2768728 | 0.72 | PTGDR2 (0.44) | MGLLFAAHPTGDR2 | |
| SCHEMBL377621 | 0.72 | CNR2 (0.36) | GRIN2BKITS1PR1CNR2 | |
| SCHEMBL2004445 | 0.71 | KCNJ1 (0.40) | MGLLKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029538-B1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | SEAL JONATHAN THOMAS | 2011-11-10 | — | — | US | disclosed |
| US-8012981-B2 | Benzylpiperazine derivatives as motilin receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275815-A1 | BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS | GPR68, GPR52, GPR88 | MGLL 1468/4885FAAH 1304/4885GRIN2B 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.